Strategic partnerships Forge Biologics is actively expanding its partner network through development and manufacturing collaborations with organizations like TECPR2 Research Foundation, Restore Vision, Skylark Bio, Epicrispr Biotechnologies, and Progeria Research Foundation, indicating ongoing opportunities for joint gene therapy programs and CMC support.

AAV manufacturing focus The company emphasizes its FUEL AAV manufacturing platform and end-to-end capabilities from process development to regulatory support, signaling strong potential for customers seeking scalable GMP-compliant AAV production and analytics.

Therapeutic diversity Engagements span diverse indications including ultra-rare neurodegenerative diseases, retinal therapies, and muscular/facial syndromes, suggesting opportunities to offer manufacturing and development services across multiple gene therapy modalities and therapeutic areas.

Financing and scale With substantial funding and revenue in the hundreds of millions, Forge Biologics is positioned to pursue larger partnerships, co-development deals, and more expansive manufacturing programs for late-stage or IND-enabling studies.

Global collaboration Recent partnerships span multiple states and international programs (Florida, Ohio, Massachusetts, Japan), highlighting a global appetite for collaboration, potential to target multinational clinical programs, and capacity to support cross-border regulatory and supply chain needs.